MARVELD3 and hepatocellular carcinoma: To verify this result, NF-κB activity inhibitor BAY 11–7082 was used to treat cells and the result demonstrated that inhibition of marvelD3 in HCC cell migration was partly mediated through the NF-κB pathway.